Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,779,520
  • Shares Outstanding, K 2,439,004
  • Annual Sales, $ 47,922 M
  • Annual Income, $ 6,016 M
  • EBIT $ 11,366 M
  • EBITDA $ 15,247 M
  • 60-Month Beta 0.45
  • Price/Sales 2.18
  • Price/Cash Flow 8.99
  • Price/Book 1.37

Options Overview Details

View History
  • Implied Volatility 29.08% (+0.11%)
  • Historical Volatility 19.00%
  • IV Percentile 79%
  • IV Rank 35.62%
  • IV High 48.01% on 04/08/25
  • IV Low 18.61% on 02/20/25
  • Expected Move (DTE 35) 2.91 (6.22%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 623
  • Volume Avg (30-Day) 2,717
  • Put/Call OI Ratio 1.33
  • Today's Open Interest 85,769
  • Open Int (30-Day) 82,635
  • Expected Range 43.80 to 49.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.84
  • Number of Estimates 6
  • High Estimate 0.86
  • Low Estimate 0.80
  • Prior Year 0.70
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.65 +0.09%
on 01/16/26
49.34 -5.37%
on 01/09/26
-0.75 (-1.58%)
since 12/16/25
3-Month
46.65 +0.09%
on 01/16/26
52.68 -11.37%
on 11/13/25
-3.33 (-6.66%)
since 10/16/25
52-Week
44.62 +4.65%
on 09/30/25
60.12 -22.33%
on 03/10/25
-4.05 (-7.98%)
since 01/16/25

Most Recent Stories

More News
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 219.44 (-0.06%)
LLY : 1,043.99 (+1.07%)
ABBV : 215.46 (+0.20%)
GSK : 48.51 (-1.24%)
CSLLY : 58.6600 (+0.20%)
PFE : 25.72 (-0.66%)
SNY : 46.70 (-1.62%)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

NEW YORK and NEW ORLEANS , Dec. 30, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating...

DVAX : 15.60 (-0.13%)
SNY : 46.70 (-1.62%)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation...

DVAX : 15.60 (-0.13%)
SNY : 46.70 (-1.62%)
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent...

SAN.FP : 80.780 (-1.04%)
REGN : 732.25 (-1.30%)
SNY : 46.70 (-1.62%)
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years...

SAN.FP : 80.780 (-1.04%)
REGN : 732.25 (-1.30%)
SNY : 46.70 (-1.62%)
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medidata , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their...

SAN.FP : 80.780 (-1.04%)
SNY : 46.70 (-1.62%)
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medidata , a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an...

SAN.FP : 80.780 (-1.04%)
SNY : 46.70 (-1.62%)
Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

SNY : 46.70 (-1.62%)
Sanofi (SNYNF) Gets a Buy from J.P. Morgan

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Sanofi, with a price target of €105.00. The company’s shares closed yesterday at $95.03.Elevate Your Investing...

SNYNF : 92.1980 (-1.16%)
SNY : 46.70 (-1.62%)
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi

CHICAGO , Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced...

SAN : 12.16 (+0.41%)
SNY : 46.70 (-1.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 48.24
2nd Resistance Point 47.94
1st Resistance Point 47.70
Last Price 46.70
1st Support Level 47.17
2nd Support Level 46.87
3rd Support Level 46.63

See More

52-Week High 60.12
Fibonacci 61.8% 54.19
Fibonacci 50% 52.37
Fibonacci 38.2% 50.54
Last Price 46.70
52-Week Low 44.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar